

Clinical Application of Active Middle Ear Implants (AMEIs)

Elizabeth M. Adams, PhD, CCC-A

Reference List

Banakís Hartl RM, Jenkins HA. Implantable hearing aids: where are we in 2020? *Laryngoscope Investigative Otolaryngology*. 2020;5:1184–1191. <https://doi.org/10.1002/lio2.495>.

Bruschini L, Berrettini S, Forli F, Murri A, Cuda D. The Carina® middle ear implant: surgical and functional outcomes. *European Archives of Oto-Rhino-Laryngology*. 2016;273. 10.1007/s00405-016-3998-1.

De Vito A, Bruschini L, Forli F, Berrettini S. Implantable hearing aids in otosclerosis: indications, surgical applications, and cost-effectiveness. *Acta Otorhinolaryngol Ital*. 2025 Jun;45(Suppl. 1):S49-S52. doi: 10.14639/0392-100X-suppl.1_3-45-2025-A1340. PMID: 40534442; PMCID: PMC12180551.

Envoy Medical Corporation. Esteem. U.S. Food and Drug Administration website. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P090018>. Accessed August 11, 2025.

Lassaletta L, Sánchez-Cuadrado I, Espinosa JM, Batuecas Á, Cenjor C, Lavilla MJ, et al. Active middle ear implants. *Acta Otorrinolaringol Esp*. 2019;70:112–118.

Med-El. Vibrant Soundbridge. U.S. Food and Drug Administration website. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P990052>. Accessed August 11, 2025

Morgenstern J, Neudert M, Zahnert T, et al. Routine diagnostics prior to ear surgery—results of a survey among otorhinolaryngology departments in German-speaking countries. *HNO* (2025). <https://doi.org/10.1007/s00106-025-01557-9>

Ototronix. Maxum System. U.S. Food and Drug Administration website. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P010023>. Accessed August 11, 2025.

Pelosi S, Carlson M, Glasscock M. The Ototronix MAXUM system: indications, techniques, and outcomes. *Operative Techniques in Otolaryngology: Head and Neck Surgery*. 2014;25(4), 338-343.